Efficacy of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's Disease

被引：0
|
作者：
Hauser, Robert [2 ]
Dzyngel, Bruce [1 ]
Bilbault, Thierry [1 ]
Shill, Holly
Argo, Albert [1 ]
机构：
[1] Cynapsus Therapeut Inc, Toronto, ON, Canada
[2] Movement Disorders Ctr, Tampa, FL USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.335
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: preliminary results from the Phase 3 study dose titration phase
    Isaacson, S.
    Espay, A.
    Pahwa, R.
    Truong, D.
    Pappert, E.
    Gardzinski, P.
    Dzyngel, B.
    Agro, A.
    Fernandez, H.
    Hauser, R.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S177 - S178
  • [22] Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease from OFF to fully ON
    Shill, H.
    Pappert, E. J.
    Agro, A.
    Dzyngel, B.
    Bilbault, T.
    Isaacson, S.
    Hauser, R.
    MOVEMENT DISORDERS, 2016, 31 : S271 - S271
  • [23] Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from a Phase 3 double-blind, placebo-controlled trial
    Pahwa, R.
    Hauser, R.
    Worden, M.
    Bhargava, P.
    Vakili, G.
    Agro, A.
    Blum, D.
    Olanow, W.
    Navia, B.
    MOVEMENT DISORDERS, 2018, 33 : S165 - S165
  • [24] Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease(PD) from OFF to fully ON
    Fernandez, H.
    Isaacson, S.
    Espay, A.
    Pahwa, R.
    Truong, D.
    Pappert, E.
    Gardzinski, P.
    Dzyngel, B.
    Agro, A.
    Hauser, R.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S178 - S178
  • [25] SAFETY OF SUBLINGUAL APOMORPHINE FILM (APL-130277) FOR THE TREATMENT OF OFF-EPISODES IN SUBJECTS WITH PARKINSON'S DISEASE: PRELIMINARY RESULTS FROM THE PHASE-3 STUDY DOSE TITRATION PHASE
    Fernandez, H. H.
    Isaacson, S.
    Espay, A. J.
    Pahwa, R.
    Truong, D.
    Pappert, E.
    Agro, A.
    Hauser, R. A.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E82 - E82
  • [26] Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL-130277) in patient with Parkinson's disease
    Fernandez, Hubert
    Isaacson, Stuart
    Espay, Alberto
    Pahwa, Rajesh
    Truong, Daniel
    Pappert, Eric J.
    Gardzinski, Peter
    Dzyngel, Bruce
    Agro, Albert
    Hauser, Robert A.
    NEUROLOGY, 2017, 88
  • [27] Efficacy of apomorphine sublingual film versus subcutaneous apomorphine for the treatment of OFF episodes in Parkinson's Disease
    Stocchi, F.
    Rascol, O.
    Poewe, W.
    Chaudhuri, R.
    Kassubek, J.
    Manzanares, L. Lopez
    Leta, V.
    Zhang, I.
    Bowling, A.
    Wu, S.
    Pappert, E.
    MOVEMENT DISORDERS, 2022, 37 : S356 - S356
  • [28] APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa
    Shill, H.
    Pappert, E. J.
    Agro, A.
    Dzyngel, B.
    Bilbault, T.
    Hauser, R.
    Isaacson, S.
    MOVEMENT DISORDERS, 2016, 31 : S274 - S274
  • [29] Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of "OFF" Episodes in Patients With Parkinson's Disease
    Olanow, C.
    Stocchi, F.
    Wilks, K.
    Peckham, E.
    De Pandis, M.
    Sciarappa, K.
    Kleiman, R.
    Blum, D.
    Navia, B.
    MOVEMENT DISORDERS, 2019, 34
  • [30] Minimum MDS-UPDRS part III change needed to convert a Parkinson's disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)
    Shill, H.
    Agro, A.
    Pappert, E. J.
    Dzyngel, B.
    Bilbault, T.
    Isaacson, S.
    Hauser, R.
    MOVEMENT DISORDERS, 2016, 31 : S275 - S275
12345